Literature DB >> 8784608

Phage specific for Vibrio cholerae O139 Bengal.

M J Albert1, N A Bhuiyan, A Rahman, A N Ghosh, K Hultenby, A Weintraub, S Nahar, A K Kibriya, M Ansaruzzaman, T Shimada.   

Abstract

From the stool of a Vibrio cholerae O139 Bengal-infected patient, a phage that specifically lysed capsulated V. cholerae O139 strains only was isolated. The phage is useful for the confirmatory diagnosis of V. cholerae O139 infection and for the differentiation of variants that lack the capsule.

Entities:  

Mesh：

Year:  1996        PMID： 8784608      PMCID： PMC229133     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  10 in total

1.  Isolation and morphological characterization of El Tor cholera phages.

Authors:  A N Ghosh; M Q Ansari; G C Datta
Journal:  J Gen Virol       Date:  1989-08       Impact factor: 3.891

Review 2.  Bacteriophage taxonomy in 1987.

Authors:  H W Ackermann
Journal:  Microbiol Sci       Date:  1987-07

3.  Vibrio cholerae O139 synonym bengal is closely related to Vibrio cholerae El Tor but has important differences.

Authors:  J A Johnson; C A Salles; P Panigrahi; M J Albert; A C Wright; R J Johnson; J G Morris
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

Review 4.  Vibrio cholerae O139 Bengal.

Authors:  M J Albert
Journal:  J Clin Microbiol       Date:  1994-10       Impact factor: 5.948

5.  Cholera isolates in relation to the "eighth pandemic".

Authors:  M Rivas; C Toma; E Miliwebsky; M I Caffer; M Galas; P Varela; M Tous; A M Bru; N Binsztein
Journal:  Lancet       Date:  1993-10-09       Impact factor: 79.321

6.  Large epidemic of cholera-like disease in Bangladesh caused by Vibrio cholerae O139 synonym Bengal. Cholera Working Group, International Centre for Diarrhoeal Diseases Research, Bangladesh.

Authors: 
Journal:  Lancet       Date:  1993-08-14       Impact factor: 79.321

7.  Vibrio cholerae O139 Bengal possesses a capsular polysaccharide which may confer increased virulence.

Authors:  A Weintraub; G Widmalm; P E Jansson; M Jansson; K Hultenby; M J Albert
Journal:  Microb Pathog       Date:  1994-03       Impact factor: 3.738

8.  FK phage for differentiating the classical and El T or groups of Vibrio cholerae.

Authors:  K Takeya; T Otohuji; H Tokiwa
Journal:  J Clin Microbiol       Date:  1981-08       Impact factor: 5.948

9.  The Vibrio cholerae O139 serogroup antigen includes an O-antigen capsule and lipopolysaccharide virulence determinants.

Authors:  M K Waldor; R Colwell; J J Mekalanos
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-22       Impact factor: 11.205

10.  The capsule and O antigen in Vibrio cholerae O139 Bengal are associated with a genetic region not present in Vibrio cholerae O1.

Authors:  L E Comstock; D Maneval; P Panigrahi; A Joseph; M M Levine; J B Kaper; J G Morris; J A Johnson
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441
  10 in total
  12 in total

1.  Shigella dysenteriae type 1-specific bacteriophage from environmental waters in Bangladesh.

Authors:  Shah M Faruque; Nityananda Chowdhury; Rasel Khan; M Rubayet Hasan; Jebun Nahar; M Johirul Islam; Shinji Yamasaki; A N Ghosh; G Balakrish Nair; David A Sack
Journal:  Appl Environ Microbiol       Date:  2003-12       Impact factor: 4.792

2.  Phenotypic and genotypic changes in Vibrio cholerae O139 Bengal.

Authors:  M J Albert; N A Bhuiyan; K A Talukder; A S Faruque; S Nahar; S M Faruque; M Ansaruzzaman; M Rahman
Journal:  J Clin Microbiol       Date:  1997-10       Impact factor: 5.948

3.  The cyclic AMP (cAMP)-cAMP receptor protein signaling system mediates resistance of Vibrio cholerae O1 strains to multiple environmental bacteriophages.

Authors:  M Shamim Hasan Zahid; T M Zaved Waise; M Kamruzzaman; Amar N Ghosh; G Balakrish Nair; John J Mekalanos; Shah M Faruque
Journal:  Appl Environ Microbiol       Date:  2010-05-14       Impact factor: 4.792

4.  RS1 element of Vibrio cholerae can propagate horizontally as a filamentous phage exploiting the morphogenesis genes of CTXphi.

Authors:  Shah M Faruque; M Kamruzzaman; Ranjan K Nandi; A N Ghosh; G Balakrish Nair; John J Mekalanos; David A Sack
Journal:  Infect Immun       Date:  2002-01       Impact factor: 3.441

5.  Enhanced L-phenylalanine production by recombinant Escherichia coli BR-42 (pAP-B03) resistant to bacteriophage BP-1 via a two-stage feeding approach.

Authors:  Haiyan Zhou; Xianyan Liao; Long Liu; Tianwen Wang; Guocheng Du; Jian Chen
Journal:  J Ind Microbiol Biotechnol       Date:  2010-11-21       Impact factor: 3.346

6.  Phagocytosis of Vibrio cholerae O139 Bengal by human polymorphonuclear leukocytes.

Authors:  M J Albert; F Qadri; N A Bhuiyan; S M Ahmad; M Ansaruzzaman; A Weintraub
Journal:  Clin Diagn Lab Immunol       Date:  1999-03

7.  Effect of exopolysaccharides on phage-host interactions in Lactococcus lactis.

Authors:  Hélène Deveau; Marie-Rose Van Calsteren; Sylvain Moineau
Journal:  Appl Environ Microbiol       Date:  2002-09       Impact factor: 4.792

8.  Host exopolysaccharide quantity and composition impact Erwinia amylovora bacteriophage pathogenesis.

Authors:  Dwayne R Roach; David R Sjaarda; Alan J Castle; Antonet M Svircev
Journal:  Appl Environ Microbiol       Date:  2013-03-15       Impact factor: 4.792

9.  An experimental study of phage mediated bactericidal selection & emergence of the El Tor Vibrio cholerae.

Authors:  M Shamim Hasan Zahid; Zaved Waise; M Kamruzzaman; A N Ghosh; G Balakrish Nair; S A M Khairul Bashar; John J Mekalanos; Shah M Faruque
Journal:  Indian J Med Res       Date:  2011-02       Impact factor: 2.375

10.  Whole genome sequencing and comparative genomic analyses of two Vibrio cholerae O139 Bengal-specific Podoviruses to other N4-like phages reveal extensive genetic diversity.

Authors:  Derrick E Fouts; Jochen Klumpp; Kimberly A Bishop-Lilly; Mathumathi Rajavel; Kristin M Willner; Amy Butani; Matthew Henry; Biswajit Biswas; Manrong Li; M John Albert; Martin J Loessner; Richard Calendar; Shanmuga Sozhamannan
Journal:  Virol J       Date:  2013-05-28       Impact factor: 4.099
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.